CN109715144A - 使用双胍类治疗发育障碍的方法 - Google Patents

使用双胍类治疗发育障碍的方法 Download PDF

Info

Publication number
CN109715144A
CN109715144A CN201780057960.3A CN201780057960A CN109715144A CN 109715144 A CN109715144 A CN 109715144A CN 201780057960 A CN201780057960 A CN 201780057960A CN 109715144 A CN109715144 A CN 109715144A
Authority
CN
China
Prior art keywords
syndrome
patient
metformin
epilepsy
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780057960.3A
Other languages
English (en)
Chinese (zh)
Inventor
马修·杜林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ovid Medical Co
Original Assignee
Ovid Medical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Medical Co filed Critical Ovid Medical Co
Publication of CN109715144A publication Critical patent/CN109715144A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C07C279/26—X and Y being nitrogen atoms, i.e. biguanides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201780057960.3A 2016-08-18 2017-08-18 使用双胍类治疗发育障碍的方法 Pending CN109715144A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662376488P 2016-08-18 2016-08-18
US62/376,488 2016-08-18
PCT/US2017/047505 WO2018035408A1 (en) 2016-08-18 2017-08-18 Methods of treating developmental disorders with biguanides

Publications (1)

Publication Number Publication Date
CN109715144A true CN109715144A (zh) 2019-05-03

Family

ID=61190982

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780057960.3A Pending CN109715144A (zh) 2016-08-18 2017-08-18 使用双胍类治疗发育障碍的方法

Country Status (9)

Country Link
US (2) US10123979B2 (enExample)
EP (1) EP3484452A4 (enExample)
JP (1) JP2019524834A (enExample)
KR (1) KR20190039974A (enExample)
CN (1) CN109715144A (enExample)
AU (1) AU2017313823A1 (enExample)
CA (1) CA3033967A1 (enExample)
MX (1) MX2019001937A (enExample)
WO (1) WO2018035408A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113318111A (zh) * 2021-06-21 2021-08-31 浙江大学 Nav1.1激动剂在制备治疗自闭症的药物中的应用

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2970884A4 (en) 2013-03-14 2016-11-02 Univ Florida DI-AMINO ACID-REINFORCED PROTEINS ASSOCIATED WITH ALS
WO2016196324A1 (en) 2015-05-29 2016-12-08 University Of Floridia Research Foundation, Inc. Methods for diagnosing huntington's disease
US10940161B2 (en) 2016-04-04 2021-03-09 University Of Florida Research Foundation, Incorporated Manipulation of EIF3 to modulate repeat associated non-ATG (RAN) translation
WO2018035408A1 (en) 2016-08-18 2018-02-22 Ovid Therapeutics Inc. Methods of treating developmental disorders with biguanides
JP7526455B2 (ja) 2017-04-17 2024-08-01 ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． ＰＫＲおよびｅＩＦ２Ａ－Ｐ経路によるＲＡＮタンパク質翻訳の調節
JP7350337B2 (ja) 2017-09-26 2023-09-26 ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． 神経障害の処置においてｒａｎタンパク質レベルを低下させるためのメトホルミンおよびそのアナログの使用
GB201912760D0 (en) * 2019-09-05 2019-10-23 Healx Ltd Treatment
JP7620988B2 (ja) 2019-09-20 2025-01-24 ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． 血清および組織ライセートからのｒａｎタンパク質に対する抗体の検出
GB202008699D0 (en) * 2020-06-09 2020-07-22 Healx Ltd Treatment
EP4440560A1 (en) * 2021-12-01 2024-10-09 University Of Florida Research Foundation, Incorporated Small molecule inhibitors of repeat associated non-aug (ran) translation and combination therapies

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1158999C (zh) * 1998-03-20 2004-07-28 安得克斯制药公司 具有单一核心的控释口服片剂
US20080188457A1 (en) * 2007-02-02 2008-08-07 Braincells, Inc. Modulation of Neurogenesis with Biguanides and GSK3-beta Agents
CN102058888A (zh) * 2009-05-01 2011-05-18 常州高新技术产业开发区三维工业技术研究所有限公司 一种治疗能量代谢异常的药物组合物和其应用
US20140256820A1 (en) * 2010-12-13 2014-09-11 Fukuoka University Therapeutic agent for blood-brain barrier disruption syndrome
CN105682688A (zh) * 2013-06-26 2016-06-15 雷特综合征研究信托 Rett综合征及其治疗

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214387B2 (en) * 2002-08-02 2007-05-08 Penwest Pharmaceuticals Company Sustained release formulations of metformin
US20060147947A1 (en) * 2002-12-04 2006-07-06 Javier Apfeld AMPK pathway components
US8252321B2 (en) * 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
WO2018035408A1 (en) 2016-08-18 2018-02-22 Ovid Therapeutics Inc. Methods of treating developmental disorders with biguanides

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1158999C (zh) * 1998-03-20 2004-07-28 安得克斯制药公司 具有单一核心的控释口服片剂
US20080188457A1 (en) * 2007-02-02 2008-08-07 Braincells, Inc. Modulation of Neurogenesis with Biguanides and GSK3-beta Agents
CN102058888A (zh) * 2009-05-01 2011-05-18 常州高新技术产业开发区三维工业技术研究所有限公司 一种治疗能量代谢异常的药物组合物和其应用
US20140256820A1 (en) * 2010-12-13 2014-09-11 Fukuoka University Therapeutic agent for blood-brain barrier disruption syndrome
CN105682688A (zh) * 2013-06-26 2016-06-15 雷特综合征研究信托 Rett综合征及其治疗

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOANNE S. ALLARD ET AL: "Prolonged metformin treatment leads to reduced transcription of Nrf2 and neurotrophic factors without cognitive impairment in older C57BL/6J mice", 《BEHAVIOURAL BRAIN RESEARCH》 *
RACHEL E. MONYAK, B.A. ET AL: "Insulin Signaling Misregulation underlies Circadian and Cognitive Deficits in a Drosophila Fragile X Model", 《MOL PSYCHIATRY》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113318111A (zh) * 2021-06-21 2021-08-31 浙江大学 Nav1.1激动剂在制备治疗自闭症的药物中的应用

Also Published As

Publication number Publication date
US20190046480A1 (en) 2019-02-14
KR20190039974A (ko) 2019-04-16
JP2019524834A (ja) 2019-09-05
US10426746B2 (en) 2019-10-01
EP3484452A4 (en) 2020-04-01
CA3033967A1 (en) 2018-02-22
AU2017313823A1 (en) 2019-02-28
EP3484452A1 (en) 2019-05-22
MX2019001937A (es) 2019-10-02
US20180050001A1 (en) 2018-02-22
WO2018035408A1 (en) 2018-02-22
US10123979B2 (en) 2018-11-13

Similar Documents

Publication Publication Date Title
CN109715144A (zh) 使用双胍类治疗发育障碍的方法
US11096929B2 (en) Methods of treating developmental disorders with gaboxadol
ES2367868T3 (es) Uso de memantina (namenda) para tratar el autismo, la compulsividad y la impulsividad.
JP7480131B2 (ja) （ｒ）－２－（４－イソプロピルフェニル）－ｎ－（１－（５－（２，２，２－トリフルオロエトキシ）ピリジン－２－イル）エチル）アセトアミドを使用した本態性振戦の処置
AU2021257943A1 (en) Methods of treating developmental disorders and/or seizure disorders with flupirtine and/or gaboxadol
WO2020018779A1 (en) Use of phenylethylidenehydrazine to treat seizure disorders, developmental disorders, neurological disorders, behavioral disorders and addiction
HK40012437A (en) Methods of treating developmental disorders and/or seizure disorders with flupirtine

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20190503

RJ01 Rejection of invention patent application after publication